@_B_I_O_T_E_C_H_ First thing I noticed was, in the Exec Summary first page, CS mentions 3 times that.... “it’s unclear whether patients/doctors are going to take $BMRN #Roctavian, or wait for a potentially much better therapy ( $PFE / $SGMO) due to Durability issues”

Also early GTx adoption = 3%